Telmisartan Half-Life
The elimination half-life of telmisartan is approximately 24 hours 1.
Pharmacokinetic Details
Telmisartan exhibits bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours 1. This represents the longest half-life among all angiotensin receptor blockers (ARBs) 2, 3, which is a key distinguishing pharmacokinetic feature of this medication.
Clinical Implications of the 24-Hour Half-Life
Once-daily dosing adequacy: The 24-hour half-life enables sustained blood pressure control throughout the entire dosing interval, with trough plasma concentrations reaching 10-25% of peak levels 1
Accumulation characteristics: With repeated once-daily dosing, telmisartan achieves a plasma accumulation index of 1.5 to 2.0 1
Early morning blood pressure control: The prolonged half-life provides superior blood pressure reduction during the critical last 6 hours of the dosing interval (early morning hours before the next dose) compared to shorter-acting ARBs 3, 4
Trough-to-peak ratios: Clinical studies demonstrate trough/peak ratios above 80%, indicating consistent 24-hour antihypertensive efficacy 5
Important Pharmacokinetic Considerations
Hepatic impairment significantly affects half-life: In patients with hepatic dysfunction, the terminal elimination half-life extends to 27-42 hours (compared to the standard 24 hours), with absolute bioavailability approaching 100% 6. This necessitates dose reduction in hepatically impaired patients.
Half-life remains dose-independent: Terminal half-life and total clearance appear independent of dose across the therapeutic range 1.
No adjustment needed for renal impairment or age: The pharmacokinetics, including half-life, do not differ significantly in elderly patients or those with renal insufficiency 1.